Journal article
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma
RT Maziarz, EK Waller, U Jaeger, I Fleury, J McGuirk, H Holte, S Jaglowski, SJ Schuster, MR Bishop, JR Westin, S Mielke, T Teshima, V Bachanova, SR Foley, P Borchmann, GA Salles, J Zhang, R Tiwari, LB Pacaud, Q Ma Show all
Blood Advances | ELSEVIER | Published : 2020
Abstract
The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to evaluate patient-reported health-related quality of life (HRQoL) with a median follow-up of 19.3 months among patients infused with a single dose of tisagenlecleucel. Patients enrolled were ≥18 years of age with r/r DLBCL after ≥2 lines of therapy and had either undergone a failed autologous stem cell transplant or were ineligible for the procedure. Two validated HRQoL instruments, Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and Short Form-36 (SF-36) Health Survey, were use..
View full abstractGrants
Funding Acknowledgements
This study was supported and the editing of the manuscript was funded by Novartis Pharmaceuticals Corporation.